Drug Interaction Report

GENERALLY AVOID: Coadministration with ceftobiprole may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporting polypeptide (OATP) 1B1 and/or OATP1B3. The proposed mechanism is decreased clearance due to ceftobiprole-mediated inhibition of OATP1B1 and/or OATP1B3.

MANAGEMENT: Concomitant use of ceftobiprole with drugs that are substrates of OATP1B1 and/or OATP1B3 is not recommended. Clinical and laboratory monitoring may be appropriate whenever ceftobiprole is added to or withdrawn from therapy with these drugs. Dosage adjustments may be considered if an interaction is suspected. Patients should be monitored for the development of adverse effects.

MONITOR: Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury. Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury. Active liver disease or unexplained transaminase elevations are contraindications to statin use.

MANAGEMENT: Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.